Skip to main content
. Author manuscript; available in PMC: 2020 Aug 14.
Published in final edited form as: J Am Chem Soc. 2019 Aug 5;141(32):12648–12656. doi: 10.1021/jacs.9b04615

Figure 3.

Figure 3.

Inhibition of viral entry by VIQKI–cholesterol conjugates. Peptide activity against HPIV3 (A) or RSV (B) was determined by plaque reduction assay in infected cell monolayers. Cell monolayers were inoculated with 100 PFU of GFP-expressing HPIV3 or RFP-expressing RSV in the presence of various concentrations of peptides. After 90 min, overlay was added, and the plates were incubated at 37 °C for 24 h. Data were expressed as mean ± standard deviation (n = 3 separate experiments). (C) General structure of cysteine-linked peptide-cholesterol conjugates.